Schizophrenia, Metabolic Syndrome and the Opportunity for developing Pharmacist-led Toolkit for Education and Metabolic Syndrome Screening (EMESYS): A Review

• Main Authors: Julaeha, -, Umi Athiyah, -, Verra Yuliana, -, JP Ayuningtyas, -, Andi Hermansyah, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: Advanced Scientific Research 2021
• Subjects: R Medicine; RS Pharmacy and materia medica; RS1-441 Pharmacy and materia medica; RS200-201 Pharmaceutical dosage forms
• Online Access: https://repository.unair.ac.id/124449/1/Bukti%20Artikel%20C-22.pdf; https://repository.unair.ac.id/124449/4/Bukti%20Validasi%20dan%20Penilaian%20Karil%20C-22.pdf; https://repository.unair.ac.id/124449/3/Bukti%20Similarity%20C-22.pdf; https://repository.unair.ac.id/124449/2/Bukti%20Korespondensi%20C-22.pdf; https://repository.unair.ac.id/124449/; http://www.ijpronline.com/ViewArticleDetail.aspx?ID=21175; https://doi.org/10.31838/ijpr/2021.13.02.154
• Institution: Universitas Airlangga

The use of Second-Generation Antipsychotic (SGA) medications has been common for patients with Schizophrenia. However, this comes with an increased risk of metabolic syndrome event. Such condition has been a concern given the long-term period for therapy. This highlights an untapped opportunity for...